ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Tuesday, November 19, 2024

8:00AM-9:30AM: Abstract Number: L17

Allogenic CD19 CAR NK Cells Therapy in Refractory Systemic Lupus Erythematosus: An Open-label, Single Arm, Prospective and Interventional Clinical Trial

Late-Breaking Abstracts (L15–L20)

8:00AM-9:30AM: Abstract Number: L20

Automated Ultrasound System ARTHUR with AI Analysis DIANA Matches Expert Rheumatologist in Hand Joint Assessment of Rheumatoid Arthritis Patients

Late-Breaking Abstracts (L15–L20)

8:00AM-9:30AM: Abstract Number: L18

CCL19+ Fibroblasts Orchestrate Fibrotic Microenvironment via CCL19-CCR7 Axis in Systemic Sclerosis

Late-Breaking Abstracts (L15–L20)

8:00AM-9:30AM: Abstract Number: L16

Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial

Late-Breaking Abstracts (L15–L20)

8:00AM-9:30AM: Abstract Number: L19

Efficacy and Safety of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Phase 3 Study and a Pooled Analysis of Two Prospective Trials

Late-Breaking Abstracts (L15–L20)

8:00AM-9:30AM: Abstract Number: L15

LEVI-04, a Novel neurotrophin-3 Inhibitor, Substantially Improves Pain and Function Without Deleterious Effects on Joint Structure in People with Knee Osteoarthritis: A Randomized Controlled Phase II Trial

Late-Breaking Abstracts (L15–L20)

11:00AM-12:30PM: Abstract Number: 2659

A Comprehensive Approach Utilizing a Combination of Genetics, Cytological Analysis, and Imaging Techniques to Speed up the Diagnostic Process in VEXAS Patients

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

11:00AM-12:30PM: Abstract Number: 2663

ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

11:00AM-12:30PM: Abstract Number: 2690

ANCA IgG Promotion of Neutrophil Recruitment, Migration and Vascular Damage in ANCA Associated Vasculitis May Be Enhanced by Hypoxia

Abstracts: Vasculitis – ANCA-Associated II

11:00AM-12:30PM: Abstract Number: 2667

Anti-Mi2 Autoantibodies in Dermatomyositis Patients Also Recognize Autoimmune Regulator (AIRE) Protein

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II

11:00AM-12:30PM: Abstract Number: 2684

Assessment of Skin in Patients with Systemic Sclerosis Using High Frequency Ultrasound : A Comparative Study with Histology and Clinical Parameters of Skin Disease

Abstracts: Systemic Sclerosis & Related Disorders – Clinical III

11:00AM-12:30PM: Abstract Number: 2685

Association Between Gastrointestinal Bacterial Species and Radiological Features of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD): A Multicenter Study from the SSc Microbiome Consortium Project

Abstracts: Systemic Sclerosis & Related Disorders – Clinical III

11:00AM-12:30PM: Abstract Number: 2681

Association of Social Determinants of Health with Systemic Lupus Erythematosus in the United States: Nationally Representative Estimates for 2017-2021

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Targets, Outcomes & Comorbidity

11:00AM-12:30PM: Abstract Number: 2694

Associations Between Immune Checkpoint Molecules and Nasal Microbiome in ANCA-associated Vasculitis

Abstracts: Vasculitis – ANCA-Associated II

11:00AM-12:30PM: Abstract Number: 2665

Autoantibody Titers Against Specific Epitope Peptides Predict Treatment Resistance in Interstitial Lung Disease Associated with Anti-MDA5 Dermatomyositis

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].